Catherine Pauline M. Hayward

Catherine Pauline M. Hayward

Auto-generated profile, based on publicly available information

Catherine Pauline M. Hayward

Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Canada

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarco Cattaneo
Marco Cattaneo
CCChiara Cerletti
Chiara Cerletti
PHPaul Harrison
Paul Harrison
CHC. P. M. Hayward
C. P. M. Hayward
DKD. Kenny
D. Kenny
AMA. D. Michelson
A. D. Michelson
Click on the article title to read more.

1 November 1997 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
TWTheodore E. Warkentin
Theodore E. Warkentin
LELeela J. Elavathil
Leela J. Elavathil
CHCatherine P.M. Hayward
Catherine P.M. Hayward
MJMarilyn A. Johnston
Marilyn A. Johnston
JRJean I. Russett
Jean I. Russett
JKJohn G. Kelton
John G. Kelton
Platelet-mediated arterial occlusion is a well-recognized cause of limb loss in patients with heparin-induced thrombocytopenia. However, the syndrome of distal ischemic necrosis complicating the deep venous thrombosis (venous limb gangrene) sometimes associated with heparin-induced thrombocytopenia has not been well characterized. To study the pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Characterization (based on descriptive and case–control studies) of a novel syndrome of limb loss and hypothesis testing by analysis of plasma samples. Five university-associated hospitals in one medical community. Clinical and laboratory records of 158 patients with heparin-induced thrombocytopenia were reviewed to identify patients with venous limb gangrene (n = 8), limb arterial thrombosis (n = 10), and uncomplicated deep venous thrombosis (n = 58). Clinical and laboratory factors associated with venous limb gangrene, including thrombin-antithrombin complexes and vitamin K-dependent procoagulant and anticoagulant factors. Warfarin treatment was more frequently associated with venous limb gangrene than with limb arterial thrombosis (8 of 8 patients compared with 3 of 10 patients; P = 0.004). The anticoagulant effect of warfarin seemed greater in the 8 patients with venous limb gangrene than in the 58 patients who did not develop gangrene (median international normalized ratio, 5.8 compared with 3.1; P < 0.001). Compared with plasma from controls, plasma from patients with venous limb gangrene had a higher ratio of thrombin-antithrombin complex to protein C activity during warfarin treatment. No hereditable abnormalities of the protein C anticoagulant pathway were seen in any patient. Warfarin treatment of deep venous thrombosis associated with heparin-induced thrombocytopenia is a possible cause of venous limb gangrene, perhaps because of acquired failure of the protein C anticoagulant pathway to regulate thrombin generation.

13 January 2006 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CHC. P. M. Hayward
C. P. M. Hayward
PHP. Harrison
P. Harrison
MCMarco Cattaneo
Marco Cattaneo
TOT. L. Ortel
T. L. Ortel
ARA. K. Rao
A. K. Rao
THTHE PLATELET PHYSIOLOGY SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS
THE PLATELET PHYSIOLOGY SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS
Summary. Background: Closure time (CT), measured by platelet function analyzer (PFA‐100®) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time test. Aim: On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH‐SSC), a working Group was formed to review and make recommendations on the use of the PFA‐100 CT in the evaluation of platelet function within the clinical laboratory. Methods: The Medline database was searched to review the published information on the PFA‐100 CT in the evaluation of platelet disorders and platelet function. This information, and expert opinion, was used to prepare a report and generate consensus recommendations. Results: Although the PFA‐100 CT is abnormal in some forms of platelet disorders, the test does not have sufficient sensitivity or specificity to be used as a screening tool for platelet disorders. A role of the PFA‐100 CT in therapeutic monitoring of platelet function remains to be established. Conclusions: The PFA‐100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of platelet function is currently best restricted to research studies and prospective clinical trials.

30 June 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
PGPaolo Gresele
Paolo Gresele
PHPaul Harrison
Paul Harrison
Loredana BuryLoredana Bury
Loredana Bury
EFE. Falcinelli
E. Falcinelli
CGC. Gachet
C. Gachet
MCMarco Cattaneo
Marco Cattaneo
Background Diagnosis of inherited platelet function disorders (IPFDs) is important for appropriate management and to improve epidemiologic and clinical knowledge. However, there remains a lack of consensus on the diagnostic approach. Objectives To gain knowledge on the current practices for the diagnosis of IPFD worldwide. Methods A 67‐item questionnaire was distributed to the ISTH members and to the members of several national hemostasis and thrombosis societies. Results A total of 202 laboratories from 37 countries participated in the survey. The most frequent criterion to define patients with a suspected IPFD was a history of mucocutaneous bleeding and no acquired cause, but heterogeneity on the identification criteria was evident. Only 64.5% of respondents performed a direct clinical interview. On average, each laboratory studied 72 patients per year. The most commonly used laboratory equipment were the light‐transmission aggregometer, the Platelet Function Analyzer‐100, and the flow cytometer. Screening tests were platelet count, peripheral blood smear, light‐transmission aggregometry, and Platelet Function Analyzer‐100. Second‐step tests were flow cytometry, molecular genetic analysis, and electron microscopy. Methodologies varied widely. In total, ~ 14 000 patients were investigated yearly and 60% turned out to not have a defect. Of the remaining 40%, only 8.7% received a diagnosis at a molecular level. Conclusions Many laboratories worldwide are involved in the diagnosis of IPFD. A large fraction of the patients studied remain without a diagnosis. A high variability in the diagnostic approaches is evident.

1 December 2010 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
CHCatherine P.M. Hayward
Catherine P.M. Hayward
KMKaren A. Moffat
Karen A. Moffat
ARArt Anne Raby
Art Anne Raby
SISara Israels
Sara Israels
EPElizabeth Plumhoff
Elizabeth Plumhoff
JZJames L. Zehnder
James L. Zehnder
Platelet function testing is important for the diagnostic evaluation of common and rare bleeding disorders. Our study goals were to promote best practices and reduce unnecessary testing variances by developing North American guidelines on platelet function testing. Guidelines were developed by consensus for expert recommendations (minimum level for approval, 70%) that included recommendations on the evaluation and interpretation of light transmission platelet aggregometry (LTA). To assess consensus, medical opinions on recommendations were gathered from diagnostic laboratories that perform LTA, in collaboration with the Quality Management Program–Laboratory Services (QMP-LS) in Ontario, Canada (10 laboratories), and the North American Specialized Coagulation Laboratory Association (NASCOLA; 47 laboratories, 5 overlapping the QMP-LS group). Adequate consensus was achieved for all and 89% of recommendations for the QMP-LS and NASCOLA groups, respectively. The recommendations adopted provide North American laboratories with additional guidance on platelet function testing, including how to interpret LTA abnormalities.

20 May 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarco Cattaneo
Marco Cattaneo
CHC. P .M. Hayward
C. P .M. Hayward
KMK. A. Moffat
K. A. Moffat
MPM. T. Pugliano
M. T. Pugliano
YLY. Liu
Y. Liu
AMA. D. Michelson
A. D. Michelson
Background: Light transmission aggregometry (LTA) is the most common method used in clinical and research laboratories to assess platelet function. However, the method has never been standardized. Objectives: As the first step towards development of methodological guidelines, the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH) undertook a large, detailed, global survey of LTA practices. Methods: Members of ISTH and of External Quality Assurance in Thrombosis and Haemostasis organizations were invited to complete a 129 item, online questionnaire. Results were analyzed anonymously to participant identities. Results: The online supplement for this article (http://www.isth.org/Publications/OfficialCommunications/PlateletPhysiology/LightTransmissionAggregometry/tabid/201/Default.aspx) contains the full details of the study findings. 359 (244 clinical, 115 research) laboratories from 48 countries participated in the survey. LTA was widely used to assess inherited or acquired bleeding disorders. Common practices were identified in sample collection, processing and analysis and although some are generally considered acceptable, others are not ideal. The agonist concentrations used for LTA varied, and many laboratories used ADP, collagen, epinephrine and Ristocetin, at more than one concentration, in addition to arachidonic acid. The parameters commonly used to assess LTA responses were maximal amplitude or % aggregation, which was considered particularly important, in addition to the presence of a ‘secondary wave’, deaggregation, shape change and a measure of the lag phase. However, many laboratories did not have appropriate reference intervals. Conclusions: This is the largest and most detailed survey of LTA practices ever undertaken. It shows a very high variability in LTA practices worldwide, and, as a consequence, methodological standardization is necessary. The information gathered in this survey will be helpful in the development of ISTH methodological guidelines for LTA.